NICE recommends new treatment for breast and bowel cancerBMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7400.1166-d (Published 29 May 2003) Cite this as: BMJ 2003;326:1166
- Susan Mayor
The National Institute for Clinical Excellence (NICE) has, in guidance issued last week, recommended capecitabine as the second line treatment for metastatic or locally advanced breast cancer.
Capecitabine and another antimetabolite, tegafur with uracil, have been recommended as options for the first line treatment of metastatic bowel cancer. NICE recommends capecitabine in combination with docetaxel for metastatic or locally advanced breast cancer when anthracycline based treatment has failed or is unsuitable.
A committee that included NHS healthcare professionals and lay people reviewed …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial